1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
"Alzheimer's Disease Programs Initiative (ADPI) - Dementia Capable States and Communities" is currently closed and not accepting applications.
Alzheimer's Disease Programs Initiative (ADPI) - Dementia Capable States and Communities is sponsored by Administration for Community Living (ACL), Administration on Aging. This opportunity supports mission-aligned projects and measurable outcomes.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
ACL Announces Funding Opportunity for Dementia-Capable Community Health Worker Programs | ACL Administration for Community Living ACL Announces Funding Opportunity for Dementia-Capable Community Health Worker Programs ACL Announces Funding Opportunity for Dementia-Capable Community Health Worker Programs Applications due Wednesday, July 30, 2025 ACL has released the 2025 funding opportunity, "Alzheimer's Disease Programs Initiative (ADPI) - Developing Dementia-Capable Community Health Worker Programs in the National Aging Network."
Cooperative agreement grants awarded under this opportunity will support the development and expansion of dementia-capable community health worker (CHW) programs embedded in local area agencies on aging or state units on aging operating as a single planning and service area. CHWs work to improve conditions for health in communities with the highest rates of disease, disability, and death.
ADPI supports dementia-capable home and community-based services for people living with dementia and their caregivers. As a result of this initiative, ACL seeks to strengthen relationships with rural and underserved communities and address barriers to care for people living with dementia and their caregivers. An informational call for prospective applicants will be held on Wednesday, July 9, 2025, from 1:00-1:45 p.
m. ET. For security reasons, the passcode and the leader’s name will be required to join your call: Phone Number: 877-716-4291 A recording will be available soon after the call concludes at the following toll-free number: 866-490-2538.
See Notice of Funding Opportunity: HHS-2025-ACL-AOA-ADPI-0012, "Alzheimer's Disease Programs Initiative (ADPI) - Developing Dementia-Capable Community Health Worker Programs in the National Aging Network program," posted June 30, 2025. Last modified on 07/08/2025
According to the current listing, eligibility includes: State units on aging and existing dementia-capable HCBS providers with the ability to undertake the required activities. Confirm the full requirements in the official notice before applying.
The current listing shows up to $1,000,000 per year for three years. Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was July 22, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Alzheimer's Disease Programs Initiative (ADPI) - Dementia Capable States and Communities is funded by Administration for Community Living (ACL), Administration on Aging. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Seven research teams will run the first clinical trials aimed at extending human healthspan under ARPA-H PROSPR contracts worth up to $144M. The milestone-based contract model breaks every convention of federal biomedical funding.
Read articleARPA-H PROSPR program funds seven research teams up to $144M to develop the first clinical trials targeting biological aging itself, testing rapamycin analogs, semaglutide, and retrotransposon inhibitors.
Read articleARPA-H awarded $144M across 7 research teams to run the first clinical trials treating aging as a condition — not a disease. How PROSPR reshapes longevity funding and what grant seekers in biotech, academia, and health tech should know.
Read article